Breaking News: Human‑Challenge Trials for COVID‑19 Are Safe, Scientists Cheer
Picture this: 36 bright‑sprung volunteers, all healthy and between 18 and 29 years old, willingly took a bite out of the original SARS‑CoV‑2 virus and then sat in a super‑safe quarantine. No alarms, no drama—just ordinary, science‑grade data that shows the whole experiment is as safe as a well‑trimmed garden.
Why Anyone Would Do This?
Think of human challenge trials as the laboratory’s “challenge” version. Back in the day, folks used them to test malaria, flu, typhoid, and cholera. The idea? Expose a small group to the pathogen under controlled conditions, watch what happens, and gather a treasure trove of data for future vaccines and treatments.
The Study: The UK’s Brave New Approach
- Run by: Open Orphan, in partnership with Imperial College London, the UK’s vaccines task force, and Orphan’s clinical arm, hVivo.
- Participants: 36 volunteers (gender‑balanced mix of 18‑29‑year‑olds).
- Method: Deliberate exposure to the original SARS‑CoV‑2 strain.
- Setting: A fully‑contained quarantine facility.
- Follow‑up: 12 months of post‑discharge monitoring.
The Verdict? Nothing Serious Happened.
Besides a few mild side effects that didn’t make for headlines—think the typical sniffles and coughs—there were no serious adverse events. The trial model was deemed safe and well tolerated among healthy, young adults. The team called it a pivotal first step.
Looking Ahead: Delta and Beyond
Professor Chris Chiu, the lead investigator, and his Imperial crew are itching to roll this up with the Delta variant. “If the pattern holds, this could accelerate vaccine and antiviral testing, especially if real‑world transmission drops,” he explained.
Imperial is also cooking up a similar “human challenge trial” arm for the Delta strain, aiming for late 2022 roll‑out. Oxford University isn’t far behind, having launched its own trial in April, focusing on reinfections to unpack immunity nuances.
Why It Matters (And Why It’s Pretty Cool)
Imagine a world where new vaccines or meds can be vetted in a few months instead of the usual marathon of clinical trials. That’s the promise here. Not only does it speed up science, but it also gives doctors a crystal ball for the next shots of data.
So next time you hear about a human challenge trial, remember: it isn’t some horror movie plot—it’s the next frontier in the war against pandemics, and it’s going down safely, thanks to science’s daring (and fairly responsible) approach.
Clinical insights
Imperial Study Offers a Fresh Lens on Covid‑19 Spread
Recently published on a pre‑print server, the Imperial College research gives a new spin on how quickly the virus shows up and how we might tweak our health rules around it.
When Symptoms Kick In
The scientists found that, on average, people begin to feel off about just two days after they first stumble into contact with the virus. That’s a bump on the timeline compared to the common belief that Covid “lies in wait” for a full week before the first sign shows up.
Where the Virus First Makes Its Mark
- The throat is the first stop for the infection.
- By the fifth day the viral load in the nose spikes and becomes the usual hot spot for worst symptoms.
- That day also marks the highest chances of actually passing the virus on to someone else.
Testing the Reality of Transmission
Quick lateral‑flow tests turned out to be a pretty good yardstick for spotting who’s still carrying live, spreading-germs. According to the team, most people sported active virus in their noses for about 6.5 days.
The Volunteers’ Tale
They recruited 18 lucky volunteers, 16 of whom experienced the classic “cold‑like” drama: stuffy/runny nose, sneezing, sore throat, and sometimes headaches, aches, or a feverish shake‑up. None hit the dangerous “danger zone.”
- 13 volunteers temporarily lost their smell – a symptom quickly returning for everyone except three who’re still seeing improvements after a third month.
- No lung changes or serious bumps were noted.
- Only one person still had a slightly drier sense of smell six months in, and that’s steadily getting better.
Why Some Stayed Virus‑Free
Out of the final 34 folks who were part of the detailed analysis, 16 didn’t come down with the infection even after being exposed. Some had viral traces in their noses but didn’t hit the two‑positive PCR test threshold set by the researchers.
Imperial’s team plans to dig deeper into why this happened and what it might mean for our broader public‑health strategies.
Take‑away for the Public
- Symptoms can show up quicker than we thought – two days on average.
- The peak of infectiousness happens roughly five days post‑infection.
- Rapid tests are a solid proxy for who can actually spread the virus.
- Understanding these timelines could help shape earlier isolation guidelines and testing schedules.
Curious About the Next Chapter?
Stay tuned for more updates as Imperial unpacks the mystery of those who, against the odds, escaped the viral brunt.
READ ALSO: Scientists on alert over rising cases caused by Omicron cousin BA.2
